Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 120,282 | 251,453 | 141,102 | 108,973 | 71,914 |
| Cost of Goods | 11,347 | 6,337 | 5,366 | 5,571 | 5,807 |
| Gross Profit | 108,935 | 245,116 | 135,736 | 103,402 | 66,107 |
| Operating Expenses | -697,794 | 81,726 | 68,026 | 60,088 | 39,585 |
| Operating Income | 807,076 | 163,727 | 68,076 | 43,885 | 27,329 |
| Interest Expense | 35,745 | 48,276 | 13,460 | 12,842 | 11,802 |
| Other Income | 25,308 | 57,879 | 2,615 | -23,083 | 19,802 |
| Pre-tax Income | 796,639 | 173,330 | 57,231 | 7,960 | 35,329 |
| Income Tax | 167,337 | 30,009 | 44,675 | 10,327 | -192,115 |
| Net Income Continuous | 629,302 | 143,321 | 12,556 | -2,367 | 227,444 |
| Net Income Discontinuous | N/A | N/A | N/A | 731 | 0 |
| Minority Interests | N/A | N/A | N/A | N/A | -2,380 |
| Net Income | $629,302 | $143,321 | $12,556 | $-1,636 | $229,824 |
| EPS Basic Total Ops | 33.13 | 6.77 | 0.60 | -0.08 | 11.61 |
| EPS Basic Continuous Ops | 33.13 | 6.77 | 0.60 | -0.11 | 11.61 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | 0.04 | N/A |
| EPS Diluted Total Ops | 31.85 | 5.96 | 0.53 | -0.08 | 10.83 |
| EPS Diluted Continuous Ops | 31.85 | 5.96 | 0.53 | -0.11 | 10.83 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | 0.04 | N/A |
| EPS Diluted Before Non-Recurring Items | 2.11 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $870,521 | $216,947 | $91,328 | $66,448 | $40,230 |